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Objective: This study was designed to find out the frequency of cystic fibrosis in children with recurrent respiratory 
infections by performing a sweat chloride test. 
Material and Methods: This cross-sectional study was carried out from 1st September 2015 to 28th February 2016 
in the department of Pediatric Medicine at the Children’s Hospital and the Institute of Child Health, Lahore after 
ethical approval. A total of 300 cases of recurrent respiratory tract infections were included.  The sweat chloride 
test was done by using pilocarpine-induced iontophoresis and measuring chloride levels on the forearm or thigh 
by sweat analyzer at the time of induction. Cystic fibrosis was labeled if sweat chloride level ranges above 60 
mEq/L.  Data was collected on Performa and SPSS version 23 was used to analyze the data.  
Results: Mean age of patients was 6.24 ± 2.7 years with 52.7% males and 47.3% females.  Most patients (86.3%) 
have more than 5 episodes of respiratory infection in a year. Cystic fibrosis was diagnosed in 19 (6.3%) patients. 
There was no relationship between the frequency of respiratory infections in a year and cystic fibrosis (p-value 
0.78). 
Conclusion: This hospital-based study showed quite a high incidence of cystic fibrosis in our population. So 
facilities including neonatal screening along with sweat chloride testing and genetic analysis should be increased. 
Keywords: Cystic fibrosis, sweat chloride test, screening, respiratory tract infections. 




Cystic fibrosis (CF) is the common fatal autosomal 
recessive disease in the European population with a 
frequency of 1 in 5000 live births.1 The common 
presenting symptoms and signs include persistent 
chest infections, pancreatic insufficiency, and raised 
sweat chloride levels.2 However, many patients 
manifest mild or atypical symptoms and clinicians 
should be alert to suspect CF even when only a few of 
the typical features are present.3 The classic or typical 
form of CF is diagnosed if a patient demonstrates 
clinical disease in one or more organ systems and has 
elevated sweat chloride levels (≥60 mmol/L).4 Most of 
these patients have disease manifestations in multiple 
organ systems (pancreas, upper and lower respiratory 
tract, and male reproductive tract). About 2% of 
patients fulfilling diagnostic criteria for CF have a 
normal or intermediate sweat chloride result. In these 
patients, the diagnosis of CF depends upon DNA 
analysis (two copies of a disease-causing mutation in 
the CFTR gene) or on the measurement of nasal 
potential difference. This disease pattern has often 
been termed "non-classic" CF. although current 
guidelines emphasize a wide spectrum of severity in 
CF and no clear distinction between "classic" and "non-
classic" types.5 The estimated prevalence and disease 
manifestations of non-classic CF may change in near 
future, as diagnostic methods for CFTR mutations and 
dysfunction become more sensitive and are broadly 
applied.3,6 Most of the world has started neonatal 
screening based on immunoreactive trypsin (IRT) in 
capillary blood collected by heel prick after 72 hours of 
life. If IRT levels are high then further testing 
including sweat chloride and/or gene mutation 
analysis is done.7 This aims to prevent early 
complications and timely management of these 
patients. 
The prevalence of CF in the Pakistani population 
comprising individuals with diverse ethnic 
backgrounds is unknown.8 All over the world more 
than 1900 mutations are found. Only a few centers in 
Pakistan are doing gene analysis of the most common 
mutation delta 508. Therefore sweat chloride analysis 
remains the main diagnostic approach to these 
patients. Pilocarpine induced iontophoresis is done to 
stimulate the sweat glands. Chloride concentration can 
also be directly measured on the skin by a 
potentiometer.9 However, the sweat chloride 
concentrations do not correlate with the severity index 
and sweat chloride concentration does not predict 
milder pulmonary involvement in patients with cystic 
fibrosis.10 In Pediatric Department in Jordan, a cross-
sectional study involving 145 children with frequent 
chest infections were seen between January and 
December 2008 with age ranging from 2-12 years. 7.5% 
were diagnosed as having CF with a positive 
polymerase chain reaction. When the sweat chloride 
test was done, it showed a sensitivity of 100% and 
specificity was 90.3% at sweat chloride test>57 
mEq/L.11  
CF was previously taken as a disease of western 
countries12,13 and frequently missed in the Pakistani 
population due to lack of appropriate diagnostic 
facilities in the public sector and also non-
affordability.8 Respiratory infections are one of three 
major killer diseases in Pakistani children and a major 
burden on the health care system. The current study 
will help us to find the prevalence of CF in children 
with recurrent respiratory infections in the referral 
center of Punjab i.e. Children’s Hospital Lahore. The 
inclusion of CF in differential diagnosis by a 
pediatrician depends upon the real burden of disease. 
So, this study aimed to determine the frequency of CF 
in children presenting with recurrent respiratory tract 
infections using a simple diagnostic tool of sweat 
chloride test. 
 
Materials and Methods 
 
The Descriptive Cross-sectional survey was carried out 
in the Department of Pediatric Medicine at the 
Children’s Hospital and the Institute of Child Health, 
Lahore, Pakistan for 6 months from 1st September 2015 
to 28th February 2016 after ethical clearance. 300 
Children aged 12 months to 12 years of both genders 
having recurrent chest infections were included in the 
study. Recurrent respiratory tract infections were 
defined as 2 or more episodes in a single year or 3 or 
more episodes ever as determined by the history of 
high-grade fever, respiratory symptoms of difficulty 
breathing, or by labeling of lower respiratory tract 
infection by a registered medical practitioner. 
The exclusion criteria included tuberculosis 
determined by history, examination, and laboratory 
investigations. Third-degree malnutrition is 
determined by history, examination according to 
WHO guidelines. Asthma determined by history, 
examination, and pulmonary function tests when 
possible, immunodeficiency determined by history 
and laboratory investigations, congenital heart disease 
determined by history, examination and 
echocardiography, congenital airway abnormalities 
determined by history, examination and laboratory 
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investigations and congenital Pulmonary/ 
Diaphragmatic defect determined by history, 
examination and laboratory investigations. 
All patients underwent sweat chloride testing using 
Pilocarpine induced iontophoresis and measuring 
chloride levels on forearm or thigh by SM-01 Sweat 
Analyzer (SANASOL’s, Hungary) in every patient at 
the time of induction. The recording was made by the 
researcher himself on the attached proforma. CF was 
labeled if sweat chloride levels range above 60 mEq/L 
on testing with SM-01 Sweat Analyzer. 
Data analysis: The data was entered and analyzed 
using SPSS version 17.0. chai square test and 
independent t-test were used to determine the 
relationship between respiratory tract infections and 




A total of 300 patients were enrolled in the study. The 
mean age of the participants was 6.24 ± 2.7 with a 
range from 12 months to 12 years. 158 (52.7%) were 
male while 142 (47.3%) were female. The majority of 
the patients 259 (86.3%)  had more than 5 episodes of 
respiratory infection in the last 12 months while 41 
(13.7%) patients had less than 5 episodes of respiratory 
tract infections in the last 12 months. 
19 (6.3%) were diagnosed as CF while 281 (93.7%) 
were negative for the sweat chloride test. there was no 
significant difference in frequency of cystic fibrosis 
7.3% versus 6.2%, p-value .780  in patients with 
infection episodes less than 5, and infection episodes 
more than 5 respectively. 
Mean episodes of respiratory tract infection in the last 
12 months were 7.16 ± 1.4 in patients with CF  and 7.41 
± 2.07 in patients without CF which was not 
statistically different (p = 0.605).  
 
 
Figure 1: Frequency of cystic fibrosis in the study 
population 
Table 1: Relationship between the frequency of 
cystic fibrosis and episodes of respiratory infections 
 Total  Cystic fibrosis   P-












Our study gives details of patients with a history of 
recurrent respiratory infections coming to The 
Children's hospital/ICH, Lahore. CF was previously 
taken as a disease of western countries (14) and is 
frequently missed in the Pakistani population due to a 
lack of appropriate diagnostic facilities. Most countries 
are doing newborn screening to screen for cystic 
fibrosis24,25 but in our country mainstay of diagnosis 
relies on sweat chloride analysis in patients who 
experience recurrent pneumonias.21,23,26 
Recurrent respiratory infections are one of the three 
major killer diseases in Pakistani children and a major 
burden on the health care system by limiting the 
quality of life.20 Although the sensitivity and specificity 
of the sweat chloride test is not too high16,17 but this is 
a good diagnostic test when combined with gene 
mutation analysis.19  
The results of our study matched those by Jordanian 
study15 which showed a 7.5% prevalence of CF. Out of 
300 patients, only 19(6.3%) were diagnosed as having a 
positive sweat chloride test. In our sampled 
population the male and female ratio was similar, 
(52.7%) were male while (47.3%) were female, showing 
that there are changes in health-seeking behavior in 
Pakistan with both male and female-presenting to our 
tertiary care hospitals. This prevalence of CF in our 
population therefore demands a population-wise 
screening program in the form of neonatal IRT 
analysis.22 When we compare our prevalence with the 
United States, CF is found approximately one in 30,000 
Americans.18  
Similarly, to our surprise, respiratory tract infection is 
quite high in our population. 259 out of 300 
individuals (86.3%) have five or more episodes in less 
than one year. This is an alarming situation and there 
should be reasonable preventing programs to reduce 
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the burden of respiratory tract infections in our 
population. 
Although our study showed no relationship between 
the frequency of cystic fibrosis and the frequency and 
mean episodes of respiratory infections concluding 
that cystic fibrosis may not be associated with repeated 




It is concluded that the frequency of CF is quite high 
even in the Asian population like Pakistan in children. 
A further mass screening program is necessary to find 
out the prevalence of CF in the community. Early 
diagnosis of CF will not only reduce the mortality or 
morbidity associated with it but it will also improve 
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